---
title: "Flupentixol - Schizophrenia"
sidebar: mydoc_sidebar
permalink: db00875-mesh-d012559-1.html
toc: false 
---


Path ID: `DB00875_MESH_D012559_1`
{% include image.html url="images/db00875-mesh-d012559-1.png" file="db00875-mesh-d012559-1.png" alt="db00875-mesh-d012559-1" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| MESH:D005475 | Flupentixol | Drug |
| UniProt:P14416 | D(2) dopamine receptor | Protein |
| REACT:R-HSA-390651 | Dopamine receptors | Pathway |
| MESH:D012559 | Schizophrenia | Disease |
|------------|------|---------|

## Relationships

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Flupentixol | DECREASES ACTIVITY OF | D(2) Dopamine Receptor |
| D(2) Dopamine Receptor | POSITIVELY CORRELATED WITH | Dopamine Receptors |
| Dopamine Receptors | CORRELATED WITH | Schizophrenia |
|---------|-----------|---------|

Comment: Flupentixol is not approved for use in the United States. Flupentixol exists in two geometric isomers, the trans(E) and pharmacologically active cis(Z) forms.It is generally understood that positive symptoms of schizophrenia arise from a dysregulated striatal dopamine pathway, leading to hyperstimulation of D2 receptors.

Reference: 
  - [https://go.drugbank.com/drugs/DB00875](https://go.drugbank.com/drugs/DB00875)
